![tirzepatide summit trial In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight SUMMIT: Tirzepatide Improves Outcomes and](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3585945231426876830)
tirzepatide summit trial In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight SUMMIT: Tirzepatide Improves Outcomes and
USD24.71
USD45.71
Pay in 4 interest-free payments of $6.18 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
![tirzepatide summit trial In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight SUMMIT: Tirzepatide Improves Outcomes and](https://www.acc.org/-/media/Non-Clinical/Images/Latest-in-Cardiology/Articles/2024/11/W24012-SUMMIT-AHA-2024-Visual-Abstract.png)
![tirzepatide summit trial In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight SUMMIT: Tirzepatide Improves Outcomes and](https://pbs.twimg.com/media/GiyaQ0sb0AAhiuR.jpg)
![tirzepatide summit trial In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight SUMMIT: Tirzepatide Improves Outcomes and](https://m3.healio.com/~/media/slack-news/cardiology/misc/other/ct1122baum_pipeline-pulse_t1.jpg)
![tirzepatide summit trial In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight SUMMIT: Tirzepatide Improves Outcomes and](https://substackcdn.com/image/fetch/$s_!hYVL!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F8cda8604-5de6-4523-a662-5f73e5335030_1638x440.png)
